Board Change • May 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Clare Fisher was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annonce • Apr 20
Molecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712 Molecular Partners AG announced the presentation of new preclinical data across three posters at the American Association for Cancer Research Annual Meeting 2026. The first poster outlines preclinical data supporting proof-of-concept for MP0632, a logic-gated Switch-DARPin CD3 T cell engager with CD2 co-stimulation designed to selectively kill cells co-expressing mesothelin (MSLN) and epithelial cell adhesion molecule (EpCAM). MP0632 leads to regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tumors expressing only one antigen, indicating a favorable therapeutic window. In addition, the Switch-DARPin candidate allowed for safe use of potent costimulation for efficient tumor cell killing with low cytokine release profile. The data support MP0632’s potential as clinical lead candidate for the treatment of ovarian cancer and other MSLN- and EpCAM-positive solid tumors. The second poster presents a computational workflow to identify and prioritize tumor-associated antigen pairs for improved tumor-selectivity and safety in support of designing novel Switch-DARPin candidates, such as MP0632. This scalable, data-driven platform provides a strong foundation for the discovery of next-generation multispecific immunotherapies. This workflow could also be leveraged for the identification of complementary tumor antigen pairs to address heterogeneous tumors, which could enable the design of next-generation multispecific Radio-DARPin candidates. The third poster outlines the molecular characteristics of MP0712, the Company’s first 212Pb-based Radio-DARPin candidate, with high affinity binding to DLL3 and optimized half-life extended properties. MP0712’s properties are hypothesized to facilitate sustained tumor uptake through repeated DLL3 internalization-replenishment despite low cell surface density of the target, thereby supporting the attractive biodistribution profile of MP0712 observed in preclinical studies as well as in first patient imaging data from a Named Patient Access Program in South Africa using MP0712 with 203Pb. MP0712, co-developed with strategic partner Orano Med, is evaluated in an ongoing Phase 1/2a trial in the US for the treatment of patients with small cell lung cancer and other DLL3-expressing neuroendocrine cancers. Details of the presentations at AACR 2026: Logic-gated Switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer Session Category: Immunology Session Title: T Cell Engagers 1 Session Start: 4/20/2026 9:00 AM PT Session End: 4/20/2026 12:00 PM PT Location: Poster Section 10 Poster Board Number: 16 Poster Number: 1624 Logic-gated Switch-DARPin–based immune cell engagers guided by data-driven tumor-antigen profiling: A computational workflow for the development of cancer immunotherapies Session Category: Bioinformatics /Computational Biology /Systems Biology /Convergent Science Session Title: Application of Bioinformatics to Cancer Biology 3 Session Start: 4/20/2026 2:00 PM PT Session End: 4/20/2026 5:00 PM PT Location: Poster Section 1 Poster Board Number: 16 Poster Number: 2691 Molecular characteristics of MP0712, a clinical stage 212Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer Session Category: Experimental and Molecular Therapeutics Session Title: Targeted Radiopharmaceuticals and Combination Strategies in Cancer Therapy Session Start: 4/22/2026 9:00 AM PT Session End: 4/22/2026 12:00 PM PT Location: Poster Section 17 Poster Board Number: 16 Poster Number: 7197 The posters will be made available on Molecular Partners' website after the presentations. Annonce • Apr 15
Molecular Partners AG Announces Board and Committee Appointments Molecular Partners AG announced that Clare Fisher was elected by shareholders to its Board of Directors at the AGM held on April 14, 2026. Clare Fisher is currently the SVP for Global Business Development and M&A at BeOne Medicines, a global oncology company committed to discovering and developing innovative treatments for cancer patients worldwide. Clare has more than two decades of healthcare experience in leadership roles, including corporate and business development, mergers and acquisitions, and strategy. She joined BeOne from Kaleido, where she served as Chief Business Officer. Previously Clare worked at Shire plc (now Takeda), where she was Group Vice President, Global Head of Transactions and Business Development, and Interim Head of Corporate Development. She also held senior roles in business development at Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation. Clare Fisher earned a B.S. in biochemistry from the University of Bath and an MBA from Henley Management College in the U.K. Agnete Fredriksen was elected to the Nomination and Compensation Committee, in place of Steven H. Holtzman. Annonce • Mar 30
Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-Election Molecular Partners AG announced that at the Annual General Meeting will be held on April 14, 2026 Current Board member Steven H. Holtzman will not stand for re-election following 12 years of service on the BoD of Molecular Partners. Annonce • Mar 24
Molecular Partners AG, Annual General Meeting, Apr 14, 2026 Molecular Partners AG, Annual General Meeting, Apr 14, 2026, at 09:00 W. Europe Standard Time. Location: at jed events, zurcherstrasse 39, 8952 schlieren, Switzerland Annonce • Mar 20
Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple Isotopes Molecular Partners AG announced it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on March 19–20, 2026. The presentation will outline the Radio-DARPins’ suitability to different isotopes with data on two Radio-DARPin candidates, each specific for a different tumor target. The results of studies in tumor-bearing mice show highly comparable biodistribution profiles for both Radio-DARPin candidates labeled with Lutetium-177 (177Lu) or with Lead-203 (203Pb), with similar uptake and washout rates. Imaging with 177Lu can be indicative of behavior with the therapeutic isotope Actinium-225 (225Ac), and similarly with 203Pb for 212Pb. Details of the presentation DARPins for targeted alpha therapy: from promising MP0712 first in-human data to opportunities for next Radio-DARPin candidates Presenter: Daniel Steiner, Ph.D., SVP of Technology and Research Time: 9:25 am CST, Friday, March 20 Location: Meeting Room B – IND Filing and Clinical Development Progress. MP0712, Molecular Partners’ DLL3-targeted 212Pb-based Radio-DARPin candidate co-developed with strategic partner Orano Med, is in an ongoing Phase 1/2a trial in the US (NCT07278479). Imaging data of MP0712 carrying the diagnostic isotope 203Pb under compassionate care are supportive of clinical development plans of MP0712 carrying the therapeutic isotope 212Pb for patients with small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers. In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler, specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with 225Ac as therapeutic payload and 177Lu as imaging payload. Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format. DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic high affinity and specificity, small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership in the clinic, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs. Annonce • Mar 14
Molecular Partners AG to Report First Half, 2026 Results on Aug 25, 2026 Molecular Partners AG announced that they will report first half, 2026 results on Aug 25, 2026 Annonce • Dec 13
Molecular Partners AG Announces Formation of Scientific Advisory Board for Radiopharmaceuticals Molecular Partners AG announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, M.D., a globally renowned expert in the field of nuclear medicine with more than two decades of experience. Ken Herrmann is Chair of the Department of Nuclear Medicine at University Hospital Essen, Germany, and a globally recognized expert in theranostics and nuclear medicine, with extensive experience in clinical development and translational research. He previously acted as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), California, USA, and served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. Ken Herrmann completed his residency in nuclear medicine at the Technische Universität München, Germany, and holds an executive MBA from the University of Zürich, Switzerland. The SAB also includes radiopharmaceutical industry executive James Cook, previously founder and CEO of Evergreen Theragnostics (sold to Lantheus in 2025) and U.S. Chief Operating Officer at Advanced Accelerator Applications (acquired by Novartis in 2017), where his team commercially launched Lutathera and Netspot; radiochemist Prof. Jason Lewis, Ph.D., the Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center and a Deputy Director of the Sloan Kettering Institute (SKI); and medical oncologist and nuclear medicine specialist Prof. Michael Morris, M.D., Steven A. Greenberg Chair in Prostate Cancer Research and Prostate Cancer Section Head at the Memorial Sloan Kettering Cancer Center. The SAB will provide critical input on candidate development and guiding the transition from early clinical validation to late-stage trials, on platform expansion, such as exploring additional isotopes and novel targeting mechanisms, and cross-disciplinary innovation, leveraging the members’ diverse expertise to refine and challenge the company’s scientific and clinical strategies. Annonce • Nov 12
Molecular Partners AG Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025 Molecular Partners AG announced the presentation of new data on MP0712, its lead Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals (TRP) Summit Europe, highlighting first encouraging human images and supporting mechanism of action data. MP0712 is being developed with strategic partner Orano Med for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The NuMeRI team, led by Prof. Mike Sathekge, plans to report the full imaging and dosimetry data of MP0712 at the Theranostics World Congress (TWC) in January 2026. These early results are in line with previously presented pre-clinical data and further support the intended mechanism of action of MP0712. The Phase 1 Investigational New Drug (IND) application for MP0712, for the treatment of small cell lung cancer (S CLC) and other DLL3-expressing neuroendocrine cancers, has been filed. dialogue with the FDA is ongoing and, pending regulatory clearance, the Phase 1 trial is expected to initiate by the end of 2025. Annonce • Aug 26
Molecular Partners AG to Report Fiscal Year 2025 Results on Mar 12, 2026 Molecular Partners AG announced that they will report fiscal year 2025 results on Mar 12, 2026 Annonce • Aug 21
Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025 Molecular Partners AG announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company’s Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies. Martin Steegmaier joins Molecular Partners from SOTIO Biotech, a clinical-stage company developing immunotherapies for cancer, where he was CSO and lead the development of a broad pipeline of oncology programs. Martin has extensive experience from senior roles at major biotech and pharma companies, including as Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology. He previously held various positions in pharma partnering and oncology disease areas at Roche, becoming Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center in Munich, and at Boehringer Ingelheim in oncology drug discovery. Martin graduated from the Northern Arizona University and holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School. Annonce • Jun 23
Molecular Partners and Orano Med Present Preclinical Data on Mesothelin-Targeting Radio-DARPin Candidate MP0726 at SNMMI 2025 Molecular Partners AG and Orano Med announced the debut of MP0726, its Radio-DARPin candidate targeting mesothelin (MSLN) and will present preclinical data in an oral presentation at the 2025 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), taking place June 21-24 in New Orleans, LA, USA. The oral presentation outlines encouraging early preclinical proof-of-concept data showing that MP0726 binds with high affinity and selectivity to the membrane-proximal domain of MSLN without being impacted by shed MSLN. In vivo results in a MSLN tumor model show a favorable biodistribution with substantial uptake of the Radio-DARPin in MSLN-positive tumors, while other organs showed limited accumulation. Annonce • Jun 12
Molecular Partners AG Presents Positive Data from Ongoing Phase 1/2a Trial of MP0533 in AML at EHA 2025 Molecular Partners AG announced a poster presentation with positive, updated data from a Phase 1/2a trial of the tetraspecific T-cell engager MP0533 in relapsed/refractory acute myeloid leukemia (AML), at the 30 EHA (European Hematology Association) Congress, taking place in Milan on June 12–15, 2025. The poster, Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-Specific Designed Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients with Relapsed/Refractory AML or MDS/AML, outlines the impact of accelerated step-up dosing regimen (steeper and faster) of MP0533 on exposure and clinical responses in cohort 8, providing the rationale for further optimization to the dosing regimen implemented in the ongoing cohort 9.Data from cohort 8 show that 3 of 8 evaluable patients (> 30%) achieved a clinical response after the first cycle, with one patient achieving a complete response and two patients a complete response with partial hematologic recovery as best overall response. Two patients maintained a response for more than 3 months and one patient remains on treatment, maintaining a response beyond 6 months at the time of data cutoff (14 April 2025). Cohort 8 implemented a higher starting dose than cohorts 1-7, and the inclusion of an additional day of dosing, reaching the target dose by day 12, as opposed to day 15 previously.Cohort 8 data indicate that patients maintained exposure to MP0533 for a longer period of time within the predicted therapeutic range through the accelerated step-up dosing scheme, within the first cycle. Data show that patients reached over 4 days of relevant exposure, with 5 out of 8 patients displaying > 50% blast reduction. MP0533 shows an acceptable safety profile after adjustment of the target dose in cohort 8. In cohorts 1-7, where step-up dosing reached target dose by day 15, exposure to predicted therapeutic doses was limited to roughly 2 days in the first cycle, most likely due to target-mediated-drug deposition. This prior treatment protocol, despite demonstrating initial blast reductions in ~30% of patients, resulted in limited responses. Based on the encouraging antitumor activity observed in cohort 8, the amended protocol for cohort 9 and beyond includes further acceleration of the step-up dosing to reach therapeutically-relevant doses faster, increased frequency of dosing for higher cumulative MP0533 exposure, and the introduction of anti-CD20 premedication to mitigate loss of exposure, with the objective to further increase the depth and duration of responses in patients. Cohort 9 is currently dosing patients and initial data from the amended dosing scheme are expected in H2 2025. Additionally, future study cohorts will evaluate the combination of azacitidine/venetoclax with MP0533.